The Target ALS Annual Meeting

Forging collaborations on the cutting-edge of ALS research

The perfect time and place for ALS research

Each spring, the Target ALS Annual Meeting brings together members of our Innovation Ecosystem over three days to share the latest breakthroughs in ALS research, forge new collaborations, and drive progress toward effective treatments for ALS.

Our 2026 meeting had the largest attendance in history, with more than 1,200 attendees present from academic institutions, pharmaceutical and biotech companies, venture capital firms, and nonprofit organizations (in-person and virtually), reflecting the growth of both the scientists we support and the impact our work has had on expanding ALS research.

Our 2026 Meeting Report

All in for a world where Everyone Lives.

The report offers a comprehensive overview of the groundbreaking science, bold conversations, and collaborative momentum that shaped our 2026 meeting in Boston.

Read the full report

What makes the Target ALS annual meeting so groundbreaking?

The Target ALS Annual Meeting is a highly collaborative ALS conference globally for both researchers and people invested in powering ALS research.

Researchers present their unpublished ongoing work that are on the cutting-edge, and receive real-time feedback from other experts in the field.

Our annual meeting invites stakeholders from across the globe, bringing together people who rarely get the chance to collaborate in one place. The connections forged in this setting have a real, measurable impact on the direction of ALS research.

Inside the Target ALS Annual Meeting

Each spring, the Target ALS Annual Meeting brings together academic researchers, pharma/biotech experts, venture capital representatives, nonprofits, and members of the ALS community over three days to share the latest breakthroughs in ALS research, forge new collaborations, and drive progress toward effective treatments for ALS. In this webinar, we invite you inside the Target ALS Annual Meeting. Speakers Dr. Amy Easton (Target ALS), Dr. Christopher Donnelly (UT Southwestern), and Dr. Lauren Mifflin (Frazier Life Sciences) share highlights from the 2026 meeting, break down the challenges facing the field, and give their outlook on what’s next in ALS research.